Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2957117 | Journal of the American Society of Hypertension | 2014 | 23 Pages |
Abstract
Sodium-glucose co-transporter 2 (SGLT2) inhibitors represent a new class of antihyperglycemic agents that block renal sodium and glucose reabsorption and may reduce blood pressure (BP). We assessed the BP lowering ability of these agents using meta-analytic techniques. PubMed, SCOPUS, and Cochrane Central were searched through October 2013. We included fully published randomized controlled trials (RCTs) that evaluated SGLT2 inhibitors in patients with type-2 diabetes mellitus and reported change in systolic and/or diastolic BP. Subgroup analyses were performed for placebo-controlled trials and those with active controls. We also conducted meta-regression to assess for a dose-response effect, and whether baseline BP, changes in body weight, heart rate, and hematocrit were associated with the BP effects. Twenty-seven RCTs (n = 12,960 participants) were included. SGLT2 inhibitors significantly reduced both systolic BP (weighted mean difference, â4.0 mm Hg; 95% confidence interval, â4.4 to â3.5) and diastolic BP (weighted mean difference, â1.6 mm Hg; 95% confidence interval, â1.9 to â1.3) from baseline. Only canagliflozin had a significant dose-response relationship with SBP (P = .008). Significant reductions in body weight and hematocrit were seen with the SGLTs. SGLTs had no significant effect on the incidence of orthostatic hypotension (P > .05). SGLT2 inhibitors significantly reduce BP in patients with type 2 diabetes.
Related Topics
Life Sciences
Neuroscience
Endocrine and Autonomic Systems
Authors
William L. PharmD, FCCP, Lindsay R. PharmD, Daniel M. PharmD, Emily M. PharmD, Kevin W. PharmD, William B. MD, FASH, FAHA, FACP,